Description

Titan Tirzepatide (TIRZ) is a synthetic peptide that represents a breakthrough in metabolic research. As a “twincretin,” it acts as a dual agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP-1) receptors.

In clinical research settings, this dual-action approach has demonstrated a superior ability to regulate blood glucose levels and reduce adipose tissue compared to single-receptor agonists. Tirzepatide is a primary subject of study for its role in improving insulin sensitivity, delaying gastric emptying, and its significant impact on long-term weight management research. Each vial contains high-purity, lyophilized powder optimized for stability and research precision.

Key Features & Research Focus

• Dual-Action Agonist: Targets both GIP and GLP-1 receptors simultaneously.

• Metabolic Homeostasis: Extensively studied for glucose-dependent insulin secretion.

• Research Grade: 99%+ purity verified for laboratory consistency.

• Scalable Dosing: Available in multiple concentrations from 5mg to 60mg to suit diverse research protocols.